Integer Holdings Corporation (ITGR) stock plummeted 5.01% during Friday's trading session, as the medical device company faced macroeconomic headwinds and uncertainty surrounding tariffs that weighed on its fourth-quarter performance.
The company reported adjusted earnings per share of $1.43 for Q4 2024, missing analysts' estimates by 2.1%. While revenues grew 11.1% year-over-year to $449.5 million, slightly beating expectations, Integer's gross margin contracted by 110 basis points to 25.9%, raising concerns about profitability.
Oppenheimer downgraded its rating on Integer stock from "Outperform" to "Perform", citing uncertainty around potential tariff-induced structural dislocations and the stock reaching its price target. The firm stated it is "adopting a wait and see stance" on Integer, despite the company's exposure to high-growth MedTech segments.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.